

# C52

## Toxicology and Drug Testing in the Medical Laboratory



This guideline provides an overview of drug testing by medical laboratories, including testing for drugs of abuse. It discussed the preexamination, examination, and postexamination considerations for specimen collection, methods of analysis, and the reporting and interpretation of results.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeals Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

---

## Toxicology and Drug Testing in the Medical Laboratory

Patrick B. Kyle, PhD, DABCC  
Dwain C. Fuller, F-ABFT, TC-NRCC  
Uttam Garg, PhD, DABCC  
Catherine A. Hammett-Stabler, PhD, DABCC, FACB  
Eva Hoess, PhD  
Kamisha Johnson-Davis, PhD, DABCC, FACB  
Bhushan M. Kapur, PhD, FACB, FCACB  
Loralie J. Langman, PhD

Donald F. LeGatt, PhD, FCACB  
David Loughmiller  
Amadeo Pesce, PhD, DABCC  
Wadid Sadek, PharmD, MS, PhD  
Michael P. Smith, PhD, DABFT, FACB  
Ian D. Watson, PhD, FRCPath, FACB  
Carl E. Wolf, PhD, MS, F-ABFT  
Alan Wu, PhD, DABCC  
Yan Victoria Zhang, PhD

### Abstract

Clinical and Laboratory Standards Institute guideline C52— *Toxicology and Drug Testing in the Medical Laboratory* helps medical laboratories develop procedures for analyzing drugs of abuse and other compounds. C52 provides guidance on clinical toxicology testing from the initial consultation through final result reporting and interpretation, and includes a variety of specimen types, analytical procedures, and instrumentation.

This guideline discusses the most common purposes for clinical toxicology testing, including the support of emergency medicine, obstetrics and gynecology, neonatology, pediatrics, psychiatry, pain management, and addiction medicine. The primary objective is to ensure high-quality standards are maintained throughout the entire testing process, from specimen collection, processing, and analysis, through results reporting and interpretation.

Clinical and Laboratory Standards Institute (CLSI). *Toxicology and Drug Testing in the Medical Laboratory*. 3rd ed. CLSI guideline C52 (ISBN 1-56238-808-8 [Print]; ISBN 1-56238-809-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2017.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2017 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Toxicology and Drug Testing in the Medical Laboratory*. 3rd ed. CLSI guideline C52. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

### **Previous Editions:**

July 1993, February 1999, April 2007

ISBN 1-56238-808-8 (Print)  
ISBN 1-56238-809-6 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

Volume 37, Number 3

## Committee Membership

### Consensus Council

**Carl D. Mottram, RRT, RPFT,  
FAARC  
Chairholder  
Mayo Clinic  
USA**

J. Rex Astles, PhD, FACB, DABCC  
Centers for Disease Control and  
Prevention  
USA

Lucia M. Berte, MA, MT(ASCP)SBB,  
DLM, CQA(ASQ)CMQ/OE  
Laboratories Made Better!  
USA

Karen W. Dyer, MT(ASCP), DLM  
Centers for Medicare & Medicaid  
Services  
USA

Dennis J. Ernst, MT(ASCP),  
NCPT(NCCT)  
Center for Phlebotomy Education  
USA

Thomas R. Fritsche, MD, PhD, FCAP,  
FIDSA  
Marshfield Clinic  
USA

Mary Lou Gantzer, PhD, FACB  
BioCore Diagnostics  
USA

Loralie J. Langman, PhD  
Mayo Clinic  
USA

Joseph Passarelli  
Roche Diagnostics Corporation  
USA

James F. Pierson-Perry  
Siemens Healthcare Diagnostics Inc.  
USA

Andrew Quintenz  
Bio-Rad Laboratories, Inc.  
USA

Robert Rej, PhD  
New York State Department of  
Health – Wadsworth Center  
USA

Zivana Tezak, PhD  
FDA Center for Devices and  
Radiological Health  
USA

### Document Development Committee on Toxicology and Drug Testing in the Medical Laboratory

**Patrick B. Kyle, PhD, DABCC  
Chairholder  
University of Mississippi Medical  
Center  
USA**

Dwain C. Fuller, F-ABFT, TC-NRCC  
VA (Dallas) Medical Center  
USA

Uttam Garg, PhD, DABCC  
The Children's Mercy Hospital  
USA

Catherine A. Hammett-Stabler, PhD,  
DABCC, FACB  
UNC Hospitals  
USA

Eva Hoess, PhD  
Roche Diagnostics GmbH  
Germany

Loralie J. Langman, PhD  
Mayo Clinic  
USA

Amadeo Pesce, PhD, DABCC  
UCSD School of Medicine  
USA

Ian D. Watson, PhD, FRCPath,  
FACB  
University Hospital Aintree  
United Kingdom

Alan Wu, PhD, DABCC  
San Francisco General Hospital-  
University of California  
San Francisco  
USA

### Staff

Clinical and Laboratory Standards  
Institute  
USA

Luann Ochs, MS  
*Project Manager*

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Joanne P. Christopher, MA, ELS  
*Editor*

Laura Martin  
*Editor*

Michael A. Russell, MA  
*Editor*

## Acknowledgment for the Expert Panel on Clinical Chemistry and Toxicology

CLSI, the Consensus Council, and the Document Development Committee on Toxicology and Drug Testing in the Medical Laboratory gratefully acknowledge the Expert Panel on Clinical Chemistry and Toxicology for serving as technical advisors and subject matter experts during the development of this guideline.

**Johanna Camara, PhD**  
**Chairholder**  
**National Institute of Standards and Technology**  
USA

**Lorin M. Bachmann, PhD, DABCC, MT**  
**Vice-Chairholder**  
**Virginia Commonwealth University Health System**  
USA

Karl De Vore, BA, SSBB  
Bio-Rad Laboratories, Inc.  
USA

Lili Duan, PhD  
FDA Center for Devices and Radiological Health  
USA

Kamisha Johnson-Davis, PhD, DABCC, FACB  
University of Utah and ARUP Laboratories  
USA

Gregory T. Maine, PhD, FACB  
Abbott  
USA

Godwin Ogbonna, PhD  
Ortho-Clinical Diagnostics, Inc.  
USA

Curtis Oleschuk, PhD, FCACB  
Diagnostic Services of Manitoba  
Canada

David B. Sacks, MB, ChB, FRCPath  
National Institutes of Health, Department of Laboratory Medicine  
USA

## Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Toxicology and Drug Testing in the Medical Laboratory gratefully acknowledge the following volunteers for their important contributions to the development of this guideline:

Kamisha Johnson-Davis, PhD, DABCC, FACB  
University of Utah and ARUP Laboratories  
USA

Bhushan M. Kapur, PhD, FACB, FCACB  
University of Toronto  
Canada

Donald F. LeGatt, PhD, FCACB  
University of Alberta Hospital  
Canada

David Loughmiller  
Dixie Regional Medical Center  
USA

Wadid Sadek, PharmD, MS, PhD  
USA

Michael P. Smith, PhD, DABFT, FACB  
Beaumont Hospital-Royal Oak  
USA

Carl E. Wolf, PhD, MS, F-ABFT  
VCU Health  
USA

Yan Victoria Zhang, PhD  
University of Rochester Medical Center  
USA

## Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
Chapter 1: Introduction.....	1
1.1 Scope.....	1
1.2 Background.....	1
1.3 Standard Precautions.....	5
1.4 Terminology.....	5
Chapter 2: Path of Workflow.....	9
Chapter 3: Preexamination Activities for Screening Testing.....	11
3.1 Collecting and Transporting Specimens.....	11
3.2 Receiving and Inspecting Specimens and Evaluating Test Requests.....	17
Chapter 4: Examination Activities for Screening Testing.....	19
4.1 Assessing Specimen Quality, Validity, and Integrity.....	19
4.2 Performing Initial Screening.....	19
4.3 Typical Measurands.....	19
4.4 Analytical Methods for Initial Screening.....	21
4.5 Specimen and Quality Control Analysis.....	25
4.6 Screening Results Review.....	25
4.7 Cutoff Levels and Lower Limit of Detection.....	26
Chapter 5: Postexamination Activities for Screening Testing.....	29
5.1 Reporting the Screening Results.....	29
5.2 Result Interpretation.....	30
5.3 Confirmation of Presumptive Positive Screening Results.....	30
Chapter 6: Definitive Testing.....	31
6.1 Preexamination Activities for Definitive Testing.....	31
6.2 Examination Activities for Definitive Testing.....	32
6.3 Postexamination Activities for Definitive Testing.....	34
Chapter 7: Conclusion.....	38
Chapter 8: Supplemental Information.....	38
References.....	39
The Quality Management System Approach.....	44
Related CLSI Reference Materials.....	45



## Foreword

For the purposes of this guideline, it is necessary to initially define “drug.” In the broadest sense, a drug is any chemical or compound administered to produce a physiological effect. From a legal perspective, “drug” often refers to substances for which the manufacture, possession, and use are regulated by government mandates, including drugs of abuse and prescription drugs. This guideline provides an overview of the analysis of scheduled drugs, nonprescription drugs, synthetic designer drugs, and other nonscheduled compounds. Substances medical laboratories do not typically analyze, such as solvents and anabolic steroids, are beyond this guideline’s scope.

This guideline discusses the detection and quantitation of drugs and compounds in biological specimens for medical purposes. Readers should be aware that clinical toxicology and drug testing results may be used in a court of law as part of the medical record and, inadvertently, become medico-legal results. However, formal forensic testing is also outside this guideline’s scope.

This guideline provides helpful information about preexamination, examination, and postexamination procedures for both screening and definitive testing that meet clinical needs. Each laboratory needs to determine medical staff’s and patients’ expectations and support the relevant extent of testing. Every laboratory cannot reasonably be expected to test for the same drugs or offer analyses for all drugs for which analytical procedures are available. In fact, laboratories should not offer drug tests simply because the measurement procedures are readily available. Laboratory directors need to determine the appropriate offering for drug testing.

Toxicology testing has traditionally been performed in medical laboratories, and this continues to be the case for most testing. However, many point-of-care testing devices, especially screening devices for drugs of abuse, are now available.<sup>1,2</sup>

Many sources provide information about how to conduct drug testing. After extracting general information from this guideline, users should consult more specific and detailed textbooks, peer-reviewed professional journal papers, websites, and other sources. Readers need to use discretion when adapting this guideline’s recommendations to suit specific purposes and circumstances.

Clinical drug testing is readily distinguished from forensic drug testing because clinical specimens are not collected using a documented chain of custody. Clinical toxicology specimens are collected and processed following the same procedures used for other clinical specimens. Many clinical toxicology measurement procedures are quantitative, but qualitative screening tests may also be used. The results of rapid screening tests may be clinically useful, but their results may not always be confirmed by more specific methods.

Forensic testing is not usually conducted in most medical laboratories or only takes place infrequently and under unusual circumstances. However, there is the potential for situations in which the distinction between clinical and forensic testing becomes blurred. For example, a pregnant woman who undergoes drug testing as a patient but who screens positive for a drug of abuse could be referred to the authorities for prosecution for use or endangering the fetus. Testing of emergency room patients for ethanol may have forensic implications, eg, in the case of a motor vehicle accident with fatalities. It may not be possible for a laboratory to foresee all potential scenarios that can arise, and it may not have a standard operating procedure that covers all eventualities.

Guidelines for conducting drug testing in medical laboratories are presented using any number of organizational schemes. The approach in this guideline follows laboratory preexamination, examination, and postexamination workflow processes for both screening and definitive toxicology testing. This approach is consistent with other guidance documents that seek to ensure the entire laboratory testing process’s quality, from the time a test is ordered until a result is reported.

C52, 3rd ed.

Clinical and analytical toxicology are rapidly changing sciences. Although efforts have been made to include the most common issues, not all measurands, instruments, or scenarios could be included in this guideline. Therefore, these recommendations may not be applicable to all circumstances, analytical methods, or scenarios.

## **Overview of Changes**

This guideline replaces the previous edition of the approved guideline, C52-A2, published in 2007. Several changes were made in this edition, including:

- Focusing the guideline exclusively on clinical toxicology testing (in contrast to previous editions of C52, which focused extensively on clinical and forensic testing for drugs of abuse)
- Removing forensic testing, to avoid redundancy with forensic testing recommendations published by forensic organizations

**NOTE:** The content of this guideline is supported by the CLSI consensus process, and does not necessarily reflect the views of any single individual or organization.

## **Key Words**

Abused drugs, clinical toxicology, controlled substances, drug abuse, drug screen, drug testing, drugs, drugs of abuse, emergency toxicology, ethanol, forensic toxicology, intoxication, overdose, serum drug testing, substance abuse, therapeutic drugs, toxicology, urine drug testing

# Toxicology and Drug Testing in the Medical Laboratory

## Chapter 1: Introduction

This chapter includes:

- Guideline's scope and applicable exclusions
- Background information pertinent to the guideline's content
- Standard precautions information
- "Note on Terminology" that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline

### 1.1 Scope

This guideline provides laboratories with basic and general toxicology testing information for medical purposes. The guideline discusses the most common specimen types used for toxicology testing, which include urine, serum, plasma, blood, oral fluid, hair, meconium, sweat, and breath. Other matrixes that can be used for toxicology testing include, but are not limited to, gastric contents, umbilical cord and cord blood, amniotic fluid, breast milk, nails, dried blood spots, and placental tissue. However, these other matrixes are not discussed in this guideline.

The measurands considered in this guideline include drugs of abuse, therapeutic drugs, over-the-counter (OTC) medications, ethanol, and miscellaneous substances. Test methodologies include rapid screening measurement procedures designed to produce only positive or negative results (qualitative tests), routine semiquantitative and quantitative tests, and more complex definitive measurement procedures.

C52 also provides useful guidance when performing drug testing for measurands other than those specifically included and for purposes and situations not covered.

This guideline is primarily applicable to drug testing performed in medical laboratories. The information is likely applicable for drug testing performed in physician office laboratories, clinics, satellite laboratories, and other facilities, but may be less applicable in other testing venues, such as large specialized reference laboratories, dedicated forensic laboratories, and the various sites in which point-of-care "field testing" may occur.

### 1.2 Background

#### 1.2.1 Purposes of Clinical Toxicology Testing

Clinical toxicology testing is performed for medical reasons. The specimens are collected from patients to diagnose, monitor, and treat pathological conditions. Clinical toxicology testing often involves the following situations: